Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 50%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
RR 20.13 [1.25, 324]
1 study · 45 participants
Very low